Lantheus Holdings Price to Free Cash Flow Ratio 2013-2024 | LNTH

Lantheus Holdings current price to free cash flow ratio as of January 19, 2025 is 14.43.

  • Lantheus Holdings average price to free cash flow ratio for 2024 was 13.35, a 19.48% increase from 2023.
  • Lantheus Holdings average price to free cash flow ratio for 2023 was 16.58, a 63.43% decline from 2022.
  • Lantheus Holdings average price to free cash flow ratio for 2022 was 45.34, a 8.18% decline from 2021.

Price to free cash flow ratio can be defined as

Lantheus Holdings Price to Free Cash Flow Ratio 2013-2024 | LNTH

  • Lantheus Holdings average price to free cash flow ratio for 2024 was 13.35, a 19.48% increase from 2023.
  • Lantheus Holdings average price to free cash flow ratio for 2023 was 16.58, a 63.43% decline from 2022.
  • Lantheus Holdings average price to free cash flow ratio for 2022 was 45.34, a 8.18% decline from 2021.

Price to free cash flow ratio can be defined as

Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$194.8B
Boston Scientific (BSX)$139.8B
Stryker (SYK)$139.4B
EssilorLuxottica (ESLOY)$110.1B
Medtronic (MDT)$103.4B
Lonza Group Ag (LZAGY)$43.7B
Haleon (HLN)$41.2B
GE HealthCare Technologies (GEHC)$38.7B
ResMed (RMD)$34.3B
Terumo (TRUMY)$28B
Koninklijke Philips (PHG)$24.3B
Zimmer Biomet Holdings (ZBH)$20.8B
Insulet (PODD)$19.1B
Baxter (BAX)$15B
Smith & Nephew SNATS (SNN)$10.5B
Bio-Rad Laboratories (BIO)$9.6B
BellRing Brands (BRBR)$9.1B
Demant (WILYY)$8.6B
Haemonetics (HAE)$3.9B
ICU Medical (ICUI)$3.8B
Prestige Consumer Healthcare (PBH)$3.7B
Perrigo (PRGO)$3.3B
Envista Holdings (NVST)$3.2B
QuidelOrtho (QDEL)$3.1B
Shandong Weigao Medical Polymer (SHWGF)$3B
Neogen (NEOG)$2.7B
GN Store Nord (GNNDY)$2.6B
LeMaitre Vascular (LMAT)$2.1B
Green Thumb Industries (GTBIF)$1.6B
AtriCure (ATRC)$1.5B